×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Donanemab Dosing Regimens Phase 3 for Early Alzheimer's (NCT
clinical
1,337 words
KG: ent-clin-42c9e825
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:alzheimers
Contents
Donanemab Dosing Regimens Phase 3 for Early Alzheimer's (NCT05738486)
Knowledge Graph
Related Hypotheses (15)
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Lysosomal Membrane Repair Enhancement
Score: 0.45
APOE Isoform Conversion Therapy
Score: 0.44
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
Show 10 more
Related Analyses (11)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Show 6 more
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40